Excelra Publishes State of AI ML Report Highlighting 2026 Drug Discovery Advances

Excelra releases an executive report titled "State of AI/ML in Drug Discovery 2026" that surveys current applications of artificial intelligence and machine learning across pharmaceutical research, noting growing adoption in target identification and compound screening, and provides overview of recent trends in model validation and regulatory considerations.

Biotech Intelligence publishes an online article exploring how AI-driven platforms are reshaping clinical development pipelines, emphasizing faster patient stratification and predictive safety modeling as key benefits for trial efficiency, and highlights case studies from leading biotech firms.

AI/ML tools highlighted include deep‑learning models that predict molecular properties and generative algorithms that design novel chemical structures, including examples such as protein folding prediction and virtual screening, which researchers claim can shorten early‑stage discovery timelines compared with traditional methods.

Industry analysts note that the reports suggest increased investment in AI‑enabled drug discovery platforms, forecasting that pharmaceutical firms will allocate a larger share of R&D budgets toward these technologies to stay competitive, with expected double‑digit growth over the next five years.